<DOC>
	<DOCNO>NCT01417507</DOCNO>
	<brief_summary>This trial study natural history brain function , quality life , seizure control patient brain tumor undergone surgery . Learning brain function , quality life , seizure control patient brain tumor undergone surgery may help doctor learn disease find good method treatment on-going care .</brief_summary>
	<brief_title>Natural History Brain Function , Quality Life , Seizure Control Patients With Brain Tumor Who Have Undergone Surgery</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine difference average change neurocognitive function ( NCF ) score baseline time radiologic tumor progression 5 year ( whichever occurs first ) , radiologically progress non-progressed patient . SECONDARY OBJECTIVES : I . To determine difference time neurocognitive decline , define Reliable Change Index - Within subject Standard Deviation ( RCI-WSD ) , radiologically progress non-progressed patient . II . To evaluate NCF postoperative observational period progression-free survival ( PFS ) radiological progression total time study 5 year . III . To determine change cognitive function early warning biomarker radiological progression . IV . To explore effect salvage therapy cognitive outcome patient progress study period 5 year . V. To evaluate quality-of-life ( QOL ) measure European Organization Research Treatment Cancer ( EORTC ) QOL-30 QOL brain module ( BCN20 ) health utility measure European Quality Life-5 Dimensions ( EQ-5D ) , total time study 5 year . VI . To evaluate seizure control total time study 5 year . VII . To evaluate molecular correlate QOL , NCF , seizure control , PFS . VIII . To characterize aberrant molecular pathway low-grade glioma ( LGGs ) test hypothesis activation signal pathway predict bad PFS overall survival ( OS ) . IX . To explore relationship change cognitive function symptomatic progression ( define worsen seizure new progressive neurologic deficit ) clinical progression ( defined initiation treatment intervention radiotherapy , chemotherapy , additional surgery ) . OUTLINE : Patients undergo neurocognitive assessment use CogState Test battery ( Detection Test ( DET ) , Identification Test ( IDN ) , One Card Learning Test ( OCLT ) , Groton Maze Learning Test ( GMLT ) ) baseline* 12 , 24 , 36 , 42 , 48 , 54 , 60 month . Patients also complete EORTC Quality Life Questionnaire-Core 30 ( QOL-30 ) , Brain Cancer Module-20 ( BCM20 ) , European Quality Life-5 Dimensions ( EQ-5D ) questionnaires baseline* , 12 , 24 , 36 , 48 , 60 month afterwards , undergo treatment . Patients instruct complete seizure medication diary study . Patients undergo MRI scan baseline* , 12 , 24 , 36 , 48 , 60 month , time radiological , clinical , neurological failure . NOTE : * 12 week surgery .</detailed_description>
	<mesh_term>Glioma</mesh_term>
	<mesh_term>Seizures</mesh_term>
	<mesh_term>Astrocytoma</mesh_term>
	<mesh_term>Oligodendroglioma</mesh_term>
	<mesh_term>Neurotoxicity Syndromes</mesh_term>
	<criteria>Central pathology confirm diagnosis supratentorial grade II oligodendroglioma , astrocytoma , mixed oligoastrocytoma prior step 2 registration No multifocal disease , base upon follow minimum diagnostic workup : History/physical examination , include neurologic examination , within 84 day prior step 2 registration Brain MRI without contrast within 84 day prior Step 2 registration ( Note : MRI 70 day surgery preferred highly encourage ) The patient must within one follow category : Maximal safe resection minimal residual disease define follow : Removal T2/fluidattenuated inversion recovery ( FLAIR ) abnormality think primarily tumor , residual ≤ 2 cm maximal tumor diameter/T2 FLAIR abnormality MRI do within 84 day postoperatively If &gt; 2 cm postoperative residual T2/FLAIR abnormality neurosurgeon believe represent edema primarily tumor , neurosurgeon encourage repeat image within allow study period ( 84 day postoperatively ) confirm resolution edema MRI time enrollment must document ≤ 2 cm residual maximal tumor diameter/T2 FLAIR abnormality Patients required second surgery obtain maximal safe resection eligible second surgery perform within 84 day initial diagnostic procedure Age &lt; 40 ( extent resection ) Age &lt; 50 preoperative tumor diameter &lt; 4 cm ( extent resection ) Karnofsky performance status ≥ 80 % No prior invasive malignancy ( except nonmelanomatous skin cancer ) unless diseasefree minimum 3 year ( For example , carcinoma situ breast , oral cavity , cervix permissible ) Must able undergo MRI brain gadolinium No plan adjuvant radiotherapy chemotherapy surgery No 84 day ( 12 week ) since prior surgery No brain tumor recurrence No prior brain tumor surgery , radiation therapy and/or chemotherapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>